Search
- Page Path
-
HOME
> Search
Case Reports
- A Case of Achieving Partial Remission with Combination of Radiation Therapy and Sorafenib inChild-Pugh Class B Patients with Hepatocellular Carcinoma with Main Portal Vein Invasion and Lymph Node Metastasis
-
Sang Youn Hwang, Seon-Mi Lee, Jung Woo Im, Joon Suk Kim, Sang Bu Ahn, Eun Kyeong Ji, Hyun-Cheol Kang, Cheol-Won Choi, Gwang-Mo Yang
-
J Liver Cancer. 2014;14(2):120-126. Published online September 30, 2014
-
DOI: https://doi.org/10.17998/jlc.14.2.120
-
-
Abstract
PDF
- Reserved liver function is one of the most important determinants of survivial in advanced
hepatocellular carcinoma (HCC). Especially in cirrhotic patient with decompensated liver
function, sorafenib for HCC with main portal vein invasion have limited efficacy and survival
benefit. Therefore many clinicians or centers still try locoregional therapy (LRT) such as
transarterial chemoembolization (TACE), radiation therapy (RT), or combination with LRT
and sorafenib in this situation. However this multidisciplinary approach may increase
treatment related toxicity such as liver failure, etc. Recently, studies for combination of RT
and sorafenib for HCC with portal vein invasion have been tried and reported not only better
therapeutic efficacy, but also more hepatic toxicity.Based on above suggestions, we herein
offer our experience of a patient that although achieved survival gain via partial remission
of intrahepatic tumor and main portal vein thrombosis and metastatic lymph node by
combination therapy of RT and sorafenib, finally expired due to hepatictoxicity. Further study,
maybe regarding a combination of locoregional and systemic therapy, is necessary on how to
manage decompenstated cirrhotic patients with HCC with main portal vein invasion. (J Liver
Cancer 2014;14:120-126)
- A Case of Early Hepatocellular Carcinoma Treatment Combined by Transarterial Chemoembolization and Radiofrequency Ablation
-
Jun Uk Lim, Hyun Phiil Shin, Joung Il Lee, Jae Jun Park, Jung Won Jeon, Kyuseong Lim
-
Journal of the Korean Liver Cancer Study Group. 2012;12(1):32-36. Published online February 28, 2012
-
-
-
Abstract
PDF
- In most early hepatocellular carcinoma (HCC), surgical resection or liver transplantation is the first choice of treatment.
However, surgery is often impossible because of patient’s physical condition such as advanced liver cirrhosis, other
comorbidities, and radiofrequency ablation (RFA) can be used as substitute treatment. Recently, it has been reported that clinical
outcomes of transarterial chemoembolization (TACE) combined with RFA were similar to that of surgical resection. This report
describes a 49-year-old male with 1.5 cm sized HCC. Because the patient could not undergo surgical resection and the tumor was
not localized on ultrasonography (US), TACE was performed instead. But the residual tumor was still detected on follow-up
contrast enhanced US, we performed additional RFA. After combined treatment with TACE and RFA, viable portion of the
tumor was not detected on one month follow-up CT and MRI image. The patient remains well without recurrence, 12 months
after combined treatment. It is suggested that TACE combined with RFA can be an alternative choice of early small HCC
treatment.
TOP